WebFeb 10, 2024 · Purpose: Mosunetuzumab is a bispecific antibody targeting CD20 and CD3 that redirects T cells to engage and eliminate malignant B cells and is being developed for relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs). Methods: This first-in-human trial (ClinicalTrials.gov identifier: NCT02500407) evaluated the safety and … WebApr 13, 2024 · Introduction. Diffuse large B-cell lymphoma (DLBCL) is characterized by the malignant proliferation of mature B-lymphocytes. It is the most common subtype of Non-Hodgkin’s lymphoma worldwide accounting for 30%-40% of all newly diagnosed cases. 1 DLBCL is categorized according to morphology, immunohistochemical, and molecular …
Did you know?
WebMar 12, 2024 · Clinical Presentation and Diagnostic Tests. A 47-year-old man with class 3 (severe) obesity, body mass index of 51, obstructive sleep apnea, hypertension, and … Web1 day ago · LH classique (n = 56) et LHNPL (n ... M. Al-Mansour, L.H. Sehn, D. Villa, et al. Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis. ... J Clin Oncol Off J Am Soc Clin Oncol, 38 (2024), pp. 698-705. CrossRef View in Scopus Google Scholar
WebAug 8, 2024 · Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2024 Jan 10;38 (2):155-165. Rosenberg JE, O’Donnell PH, Balar AV, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 … WebSecondary hemophagocytic lymphohistiocytosis (HLH) is a rare but fatal condition with various underlying disorders in adult patients and is diagnosed based on the HLH-2004 …
WebYounes A, Sehn LH, Johnson P, et al. Randomized phase Ⅲ trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma [J]. J Clin Oncol, 2024, 37 (15): 1285-1295. DOI: 10.1200/JCO.18.02403. WebApr 10, 2024 · From March 2024 to December 2024, cfDNA was analysed from plasma samples collected in Streck tubes from all newly diagnosed patients, regardless of the amount of tumoral material available. ... according to the method described by Bohers et al. 41 using a 36-gene lymphopanel (Table S1, sheet 1) and amplicon-based libraries on an …
WebLate-onset noninfectious pulmonary complications (LONIPCs) are life threatening for allogeneic hematopoietic SCT (allo-HSCT) recipients. However, the impact of LONIPCs on … gutter xmas light clipsWebJ Clin Oncol 33:3467–3474 CrossRefPubMed Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD et al (2015) Randomized phase II trial comparing Obinutuzumab (GA101) with Rituximab in patients with relapsed CD20+ indolent B‑cell non-Hodgkin lymphoma: final analysis of the GAUSS study. J Clin Oncol 33:3467–3474 CrossRef PubMed gutter wrapWebDec 6, 2024 · Stand 2024, Zugriff 22.12.2024 www.uniklinik-ulm.de ... Role of VHL gene mutation in human cancer. J Clin Oncol 2004; 22: 4991-5004. ... Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 22: 454-63. gutter youtubeWebMar 28, 2024 · J Clin Oncol 2024;38:3672–84. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47. Lin C, Bradshaw T, Perk T, Harmon S, Eickhoff J, Jallow N, et al. . Repeatability of quantitative 18F-NaF PET: a … gutter y connectorWebApr 13, 2024 · CrossRefPubMed Sehn et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17(8):1081–93. gutter y branchWebApr 13, 2024 · BackgroundOvarian cancer is one of the most common female malignancies worldwide, and metabolic factors, such as hyperglycemia, are becoming potential risk factors. This study aimed to analyze the disease burden and its changing trend of ovarian cancer attributable to hyperglycemia in the Chinese population from 1990 to … gutter woundWebMay 11, 2024 · Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial - The Lancet Oncology Articles Volume 22, ISSUE 6, P790-800, June 2024 boy baby names that start with f